Business Description
Qualigen Therapeutics Inc
NAICS : 541713
SIC : 8731
ISIN : US74754R2022
Share Class Description:
QLGN: Ordinary SharesDescription
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.31 | |||||
| Equity-to-Asset | -1.04 | |||||
| Debt-to-Equity | -0.62 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -99.82 | |||||
| Beneish M-Score | -11.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -28.2 | |||||
| 3-Year EPS without NRI Growth Rate | -20.9 | |||||
| 3-Year FCF Growth Rate | -165.1 | |||||
| 3-Year Book Growth Rate | 38.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.97 | |||||
| 9-Day RSI | 35.02 | |||||
| 14-Day RSI | 35.35 | |||||
| 6-1 Month Momentum % | -40.45 | |||||
| 12-1 Month Momentum % | -63.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.28 | |||||
| Quick Ratio | 0.28 | |||||
| Cash Ratio | 0.1 | |||||
| Days Inventory | 244.4 | |||||
| Days Sales Outstanding | 62.98 | |||||
| Days Payable | 226.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -62.3 | |||||
| Shareholder Yield % | -4.05 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 29.44 | |||||
| Operating Margin % | -380.21 | |||||
| Net Margin % | -414.87 | |||||
| FCF Margin % | -326.22 | |||||
| ROE % | -645.42 | |||||
| ROA % | -123.1 | |||||
| ROIC % | -125.49 | |||||
| ROC (Joel Greenblatt) % | -841.44 | |||||
| ROCE % | -314.34 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.43 | |||||
| EV-to-EBIT | -0.22 | |||||
| EV-to-EBITDA | -0.23 | |||||
| EV-to-Revenue | 0.82 | |||||
| EV-to-Forward-Revenue | 0.01 | |||||
| EV-to-FCF | -0.25 | |||||
| Earnings Yield (Greenblatt) % | -454.55 | |||||
| FCF Yield % | -597.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:QLGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Qualigen Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.234 | ||
| EPS (TTM) ($) | -2.66 | ||
| Beta | 0.08 | ||
| Volatility % | 45.8 | ||
| 14-Day RSI | 35.35 | ||
| 14-Day ATR ($) | 0.031481 | ||
| 20-Day SMA ($) | 0.300635 | ||
| 12-1 Month Momentum % | -63.06 | ||
| 52-Week Range ($) | 0.27 - 1.26 | ||
| Shares Outstanding (Mil) | 6.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Qualigen Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Qualigen Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Qualigen Therapeutics Inc Frequently Asked Questions
What is Qualigen Therapeutics Inc(QLGN)'s stock price today?
The current price of QLGN is $0.28. The 52 week high of QLGN is $1.26 and 52 week low is $0.27.
When is next earnings date of Qualigen Therapeutics Inc(QLGN)?
The next earnings date of Qualigen Therapeutics Inc(QLGN) is .
Does Qualigen Therapeutics Inc(QLGN) pay dividends? If so, how much?
Qualigen Therapeutics Inc(QLGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers